BG Medicine Highlights Role of Galectin-3 Testing in Combating Hospital Readmissions at the American College of Cardiology's

BG Medicine Highlights Role of Galectin-3 Testing in Combating Hospital
Readmissions at the American College of Cardiology's (ACC) 62nd Annual
Scientific Session & Expo

WALTHAM, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD), a diagnostics company focused on the development and
commercialization of novel cardiovascular tests, today announced that company
representatives and independent researchers will highlight the clinical
utility of galectin-3 blood testing in assessing the prognosis of patients
with chronic heart failure through an extensive series of data presentations
and company-sponsored events at the American College of Cardiology's (ACC)
62nd Annual Scientific Session & Expo in San Francisco, California.

As part of BG Medicine's presence at the ACC meeting, the company will host an
educational symposium chaired by Alan Maisel, MD, Professor of Medicine, UCSD,
Director of Coronary Care Unit and Heart Failure Program at the San Diego VA
Medical Center, focused on how galectin-3 testing can help hospitals reduce
readmissions. Representatives from BG Medicine will also be sponsoring booth
N5519 which showcases how galectin-3 can impact the treatment of patients with
chronic heart failure through a series of real-life case studies.

Reducing unplanned readmissions for patients continues to be one of the most
urgent and pressing issues facing US-based hospitals today, particularly since
October 2012, when the federal Centers for Medicare & Medicaid Services (CMS)
enacted new rules that impose significant financial penalties on hospitals
with excessive 30-day hospital readmission rates. Because heart failure
patients with elevated galectin-3 are two-to-three times more likely to be
readmitted to the hospital within 30 days of discharge, we believe that
identifying these high-risk patients through galectin-3 testing is an
efficient, simple and cost-effective tool in a hospital's strategy to reduce
unplanned 30-day readmissions, enabling hospitals to better direct their
intervention strategies and resources to those who need them most.^i, ii,iii

Clinicians and hospital administrators interested in learning more about the
unique role of galectin-3 testing as a risk stratification tool in reducing
30-day hospital readmissions can register to attend the BG Medicine dinner
symposium From Emergency Department to Discharge: The Role of Biomarkers in
Preventing Readmissions at www.galectin-3.com. The program will feature
scientific and economic data from nationally-recognized experts from the
emergency department, laboratory and administrative settings.

"For patients presenting to the emergency department, the initial triage and
diagnosis by a clinician can influence the entire course of their care," said
W. Frank Peacock IV, MD, FACEP Professor, Associate Chair & Research Director,
Baylor College of Medicine and a featured panelist in the symposium. "Having
ready access to a patient's galectin-3 level early in the assessment process
may help clinicians make more informed management decisions across the
spectrum of heart failure patients. Not only does knowledge of a patient's
elevated galectin-3 provide valuable information as to which patients are in
greatest need of aggressive management and at the highest risk for
readmission, a low galectin-3 also identifies the lowest risk patients who may
be appropriate candidates for observation or possibly early discharge."

In addition to the company-sponsored activities highlighting the issue of
unplanned readmissions, independent researchers will present a range of
findings on the role of galectin-3 testing in patients with chronic heart
failure, including the following: 

  *Sat, Mar 9, 8:45 - 9:00 AM

  903-6 - Coronary Sinus Level of Galectin-3 is a Better Predictor than
  Peripheral Venous Level of Major Adverse Cardiac Events in Patients with
  Cardiac Resynchronization Therapy

  *Sat, Mar 9, 10:00 - 10:45 AM

  1136-309/309 - Usefulness of Plasma Galectin-3 in Congestive Heart Failure:
  Relationships with Echocardiographic Parameters and Survival

  *Sun, Mar 10, 3:45 - 4:30 PM

  1265-297/297 - Serial Measurement of Galectin-3 Predicts Chronic Heart
  Failure Outcomes and Ventricular Remodeling: Results from the ProBNP
  Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study

  *Sun, Mar 10, 3:45 - 4:30 PM

  1265-309/309 - The Incremental Prognostic Power of Novel Biomarkers in
  Patients with Severe Chronic Heart Failure

  *Mon, Mar 11, 9:45 - 10:30 AM

  1294-147/147 - Galectin-3 Levels Elevated in Pulmonary Hypertension

The BGM Galectin-3® test is cleared by the FDA as an aid in assessing the
prognosis of patients with chronic heart failure, in conjunction with clinical
evaluation.

About Galectin-3 and Heart Failure

Galectin-3 is a unique carbohydrate-binding lectin, or protein, that binds to
carbohydrates called beta-galactosides. Galectin-3 has been implicated in a
variety of biological processes important in the development and progression
of heart failure, and is believed to be a primary mediator of progressive
cardiac fibrosis (abnormal thickening and stiffening of the heart muscle) and
adverse remodeling (changes in the structure of the heart). Higher levels of
galectin-3 are associated with a more aggressive form of heart failure and 30%
or more of mild to moderate heart failure patients will have elevated levels
of galectin-3. Heart failure affects an estimated 5.7 million Americans, with
approximately 670,000 new cases occurring each year. The direct and indirect
cost of heart failure in the United States for 2011 is estimated to be $34.4
billion. ^iv, v

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a diagnostics company focused on the
development and commercialization of novel cardiovascular tests to address
significant unmet medical needs, improve patient outcomes and reduce
healthcare costs. The Company has two products: the BGM Galectin-3^® test for
use in patients with chronic heart failure is available in the United States
and Europe; and the CardioSCORE™ test for the risk prediction of major
cardiovascular events is expected to be launched in Europe in the first half
of 2013. For additional information about BG Medicine, heart failure and
galectin-3 testing, please visit: www.bg-medicine.com and
www.galectin-3.com.

The BG Medicine Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10352

Special Note Regarding Forward-looking Statements

Certain statements made in this news release contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of 1934, as
amended, that are intended to be covered by the "safe harbor" created by those
sections. Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can generally be
identified by the use of forward-looking terms such as "believe," "expect,"
"may," "will," "should," "could," "seek," "intend," "plan," "estimate,"
"anticipate" or other comparable terms. Forward-looking statements in this
news release address our understanding that heart failure patients with
elevated galectin-3 are two-to-three times more likely to be readmitted to the
hospital within 30 days of discharge than other heart failure patients; our
belief that identifying these high-risk patients through galectin-3 testing is
a potentially valuable and cost-effective tool in reducing unplanned
readmissions; our belief that identifying patients at greater risk with
galectin-3 testing enables hospitals to more efficiently and cost-effectively
direct intervention strategies and resources; our belief that increased usage
of galectin-3 testing by the healthcare system may improve health outcomes and
reduce healthcare costs. Forward-looking statements are based on management's
current expectations and involve inherent risks and uncertainties which could
cause actual results to differ materially from those in the forward-looking
statements, as a result of various factors including those risks and
uncertainties described in the Risk Factors and in Management's Discussion and
Analysis of Financial Condition and Results of Operations sections of our
recent filings with the Securities and Exchange Commission, including our most
recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We urge
you to consider those risks and uncertainties in evaluating our
forward-looking statements. We caution readers not to place undue reliance
upon any such forward-looking statements, which speak only as of the date
made. Except as otherwise required by the federal securities laws, we disclaim
any obligation or undertaking to publicly release any updates or revisions to
any forward-looking statement contained herein (or elsewhere) to reflect any
change in our expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based.

^i de Boer RA, Lok DJ, Jaarsma T, et al. Ann Med. 2011;43(1): 60–8.

^ii McCullough PA, Olobatoke A, and Vanhecke TE.Rev Cardiovasc Med.
2011;12(4): 200-10.

^iii de Boer RA, van Veldhuisen DJ, deFilippi C, et al. J Card Fail.
2011;17:S93.

^iv Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al.
Heart disease and stroke statistics—2012 update: a report from the American
Heart Association. Circulation. 2012;125(1):e2–220.

^v Heidenriech PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD,
et al. Forecasting the future of cardiovascular disease in the United States:
a policy statement from the American Heart Association. Circulation.
2011;123(8):933–44.

CONTACT: Chuck Abdalian
         EVP & Chief Financial Officer
         (781) 434-0210

BG Medicine Inc. logo
 
Press spacebar to pause and continue. Press esc to stop.